Recent Quotes (30 days)

You have no recent quotes
chg | %

BTG plc  

(Public, LON:BTG)   Watch this stock  
Find more results forLON:BGC
+17.00 (2.34%)
Oct 30 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 720.00 - 743.00
52 week 410.70 - 743.00
Open 726.00
Vol / Avg. 662,114.00/803,041.00
Mkt cap 2,696.89M*
P/E 108.34
Div/yield     -
EPS 0.07*
Shares 362.80M
Beta     -
Inst. own     -
Jan 26, 2015
BTG PLC Interim Management Statement (Estimated) Add to calendar
Nov 11, 2014
Half Year 2015 BTG PLC Earnings Call - 9:30am GMT - Add to calendar
Nov 11, 2014
Half Year 2015 BTG PLC Earnings Release - 8:00am GMT - Add to calendar
Oct 6, 2014
Q2 2015 BTG PLC Trading Statement Release
Sep 23, 2014
BTG PLC Investor Day (Surrey)
Sep 9, 2014
BTG PLC at Morgan Stanley Healthcare Conference

Key stats and ratios

Q1 (Mar '14) 2014
Net profit margin 0.51% 8.36%
Operating margin 1.67% 9.40%
EBITD margin - 24.30%
Return on average assets 0.19% 3.87%
Return on average equity 0.26% 5.04%
Employees 776 -
CDP Score - 55 D


5 Fleet Place
United Kingdom - Map
+44-20-75750000 (Phone)
+44-20-75750010 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology. Its focus within Specialty Pharmaceuticals is on antidote products that are used within hospitals. Its interventional medicine products are embolisation and drug-eluting beads used primarily to treat patients with liver tumors and Brachytherapy products used mainly for early-stage prostate cancer. Licensing & Biotechnology business area consists of licensed products and programmes and generates royalties for BTG. The Company�s subsidiaries include BTG International (Holdings) Ltd, Provensis Ltd, BTG International Ltd, BTG Employee Share Schemes Ltd and BTG Management Services Ltd.

Officers and directors

Louise Makin Ph.D. Chief Executive Officer, Executive Director
Rolf B. Soderstrom Chief Financial Officer, Executive Director
Paul Mussenden Company Secretary
Garry Watts MBE Non-Executive Chairman of the Board
Age: 57
Giles F. B. Kerr Senior Independent Non-Executive Director
Melanie G. Lee Ph.D., CBE Part Time Chief Scientific Officer
Age: 56
Ian F. R. Much Independent Non-Executive Director
W. James O'Shea Independent Non-Executive Director
Age: 63